However, it would allow Lilly to market Cymbalta as a pain treatment.
但是FDA还是会允许礼来公司将欣百达作为止痛药在市场上销售。
If approved, the FDA said Cymbalta would be the first nontraditional analgesic approved for chronic pain.
FDA称，如果欣百达获得批准，它将是第一个非传统慢性疼痛止痛药。
The study looked at the drug duloxetine, or Cymbalta, which is used to treat depression and generalized anxiety disorder.
这项研究针对于用于治疗抑郁症和综合焦虑失调症的度洛西汀或欣百达。
The FDA asked the panel for advice on whether use of Cymbalta should be formally expanded, given concerns about liver damage.
考虑到肝脏损伤，FDA向麻醉和生命支持顾问委员会咨询该药物是否应正式扩大适应症。
However, the panel suggested the FDA only approve Cymbalta as an additional treatment for lower back pain, and not osteoarthritis of the knee.
尽管如此，该委员会建议FDA仅仅批准该药物用于腰疼的辅助治疗，而不能治疗膝盖关节炎。
Lilly is seeking FDA approval for Cymbalta as a treatment for chronic pain conditions such as knee pain caused by osteoarthritis and lower back pain.
礼来公司正在向FDA申请将欣百达适应症扩展到慢性疼痛，例如因关节炎导致的膝盖疼痛和腰疼。
Average weekly pain scores, measured before taking Cymbalta or the placebo and again at the end of the study, showed greater improvement in the Cymbalta group.
在服用欣百达或者安慰剂之前，测量每周疼痛指数的平均值，并在研究结束时再次测量。结果表明服用欣百达的一组患者有更明显的改善。
The study in which Cymbalta didn't beat the placebo also included a lower (20 milligram) dose of Cymbalta, as well as the 60 milligram dose, 120 milligram dose, and placebo.
而那项欣百达未能打败安慰剂的研究中，包含更低的20mg欣百达剂量组，以及60 mg欣百达、120 mg欣百达和安慰剂。
In both studies, side effects more commonly reported by patients taking Cymbalta included nausea, dry mouth, fatigue, diarrhea, excessive sweating (hyperhidrosis), dizziness, and constipation.
在两项研究中，患者服用欣百达后，报告的常见副作用包括恶心、口干、疲劳、腹泻、过量出汗(多汗症)、头晕和便秘。
The FDA wrote that a print AD for Cymbalta "entirely omits risk information" in the main part of the AD and directs readers to a single-spaced paragraph on another page that included unrelated ads.
FDA在1月7日的一份通报中指出，一种欣百达的印刷广告在其主要内容中“完全省去了风险信息”，并将读者引入另一页第一行没有空格的段落里，那里包含的是毫无关系的广告。
The FDA wrote that a print AD for Cymbalta "entirely omits risk information" in the main part of the AD and directs readers to a single-spaced paragraph on another page that included unrelated ads.
FDA在1月7日的一份通报中指出，一种欣百达的印刷广告在其主要内容中“完全省去了风险信息”，并将读者引入另一页第一行没有空格的段落里，那里包含的是毫无关系的广告。
应用推荐